About this episode

Dr. Sonam Puri discusses the ASCO living guideline update for stage IV NSCLC with driver alterations.

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines . Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02822 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology…

People in this episode

Host: Brittany Harvey

Guest: Dr. Sonam Puri

Topics covered

• NSCLC
• driver alterations
• biomarker testing
• first-line therapies
• oncology guidelines
• clinical research

Keywords

• NSCLC
• driver alterations
• biomarker testing
• EGFR
• MET
• ROS1
• HER2
• first-line therapy
• clinical guidelines

Mentioned in this episode

Organizations: American Society of Clinical Oncology, Moffitt Cancer Center, Journal of Clinical Oncology

Books & works: Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0

Places: www.asco.org/thoracic-cancer-guidelines, ascopubs.org

More episodes of ASCO Guidelines

• Systemic Treatment of Thyroid Cancer Guideline · April 1, 2026 · 23 min
• Patient-Clinician Communication Guideline Update · March 10, 2026 · 31 min
• Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Guideline Update · February 26, 2026 · 29 min
• White Blood Cell Growth Factors Guideline Update · February 25, 2026 · 23 min
• Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 1 · February 3, 2026 · 18 min
• Systemic Therapy in Patients With mCRPC: ASCO Living Guideline 2026.1 · January 20, 2026 · 14 min

Explore listener stats, chart rankings, contacts and more on the ASCO Guidelines podcast page.